Search Results

You are looking at 1 - 1 of 1 items for :

  • Thyroid cancer - basic and translational x
Clear All
Carla Colombo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed
Close
,
Daniele Ceruti Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed
Close
,
Massimiliano Succi Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Massimiliano Succi in
Google Scholar
PubMed
Close
,
Simone De Leo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed
Close
,
Matteo Trevisan Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed
Close
,
Claudia Moneta Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed
Close
, and
Laura Fugazzola Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Close

Europe, the multikinase inhibitors sorafenib, lenvatinib (LEN) and cabozantinib have been approved for RAI-R DTC, vandetanib (VAN) and cabozantinib for MTC, and the gene-targeted selpercatinib (SELP) and larotrectinib for cancers harbouring rearranged

Open access